Pacira Advances Gene Therapy Manufacturing for Osteoarthritis Treatment
Event summary
- Pacira BioSciences transitioned PCRX-201 to a scalable commercial manufacturing process, enabling enrollment of the first patient in Part B of its Phase 2 ASCEND study.
- Topline data from Part A of the ASCEND study is expected by the end of 2026.
- PCRX-201 has received RMAT designation from the FDA and ATMP designation from the EMA.
- The ASCEND study involves approximately 135 patients with osteoarthritis of the knee.
The big picture
Pacira's transition to a scalable commercial manufacturing process for PCRX-201 aligns with its 5x30 growth strategy, positioning the company to advance one of its most promising pipeline programs. The success of this milestone further demonstrates the scalability of Pacira's proprietary HCAd platform, which is crucial for addressing common diseases like osteoarthritis. This development comes amid broader industry trends toward non-opioid pain therapies and innovative gene therapy solutions.
What we're watching
- Clinical Progress
- How the topline data from Part A of the ASCEND study will impact the progression of PCRX-201 toward late-stage development.
- Manufacturing Scalability
- Whether Pacira can sustain the scalability of its HCAd platform for future registrational studies and commercialization.
- Regulatory Pathway
- The pace at which PCRX-201 will navigate regulatory approvals given its RMAT and ATMP designations.
Related topics